Skip to main content
. 2020 Jul 30;11(7):603. doi: 10.1038/s41419-020-02788-0

Fig. 5. MiR-125a and miR-125b targeted on Stat3.

Fig. 5

a The expression of Stat3 in MSCs with or without miR-125a (20 nmol) and miR-125b (20 nmol) inhibitor treatment, analyzed by western blot. b, c Th17 cell differentiation (b) and the expression of IL-17 and RORγt (c) after control MSCs exosomes or miR-125a and miR-125b inhibitor pretreated MSC exosomes. d Sequence of miR-125a and miR-125b and the putative target sites in the 3′-UTR of Stat3 mRNA. Mutation was designed in the complementary binding sites of miR-125a and miR-125b. e Luciferase activity analysis. 293T cells were cotransfected with Renilla luciferase control vector and firefly luciferase reporter vector containing either WT or mutant 3′-UTR of Stat3, with or without treatment of miR-125a (20 nM) and miR-125b (20 nM) mimics for 24 h. Exo exosomes, In. treated Exo exosomes derived from miR-125a and miR-125b inhibitor pretreated MSCs. *P < 0.05, **P < 0.01, ***P < 0.001.